SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Change in Duties of Dr. Gregoire Cosendai.
On September 29, 2017, the Board of Directors of Second Sight Medical Products, Inc. (the “Company”) appointed Gregoire Cosendai to be Vice President Clinical Affairs. Dr. Cosendai will direct or oversee clinical activities relating to Orion I and all other clinical activities of the Company. He will continue to report to the Company’s CEO, Will McGuire. Dr. Cosendai was formerly Vice President of European Operations.
ITEM 8.01 Other Events
Effective October 1, 2017, the Company retained Frank Vandeputte, through his personal service company, to act as Vice President and General Manager, EMEA and Asia Pacific. Mr. Vandeputte is principally tasked with overseeing sales and marketing outside of North America, and will report to the Company’s CEO, Will McGuire. Mr. Vandeputte has extensive international sales and marketing experience in the medical device industry, including with multiple start-up companies.
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
